Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Coherus Bio (CHRS)

Coherus Bio (CHRS)
1.0000 x 11 1.0200 x 98
Post-market by (Cboe BZX)
1.0300 +0.0200 (+1.98%) 04/25/25 [NASDAQ]
1.0000 x 11 1.0200 x 98
Post-market 1.0000 -0.0300 (-2.91%) 17:31 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.9900
Day High
1.0500
Open 1.0100
Previous Close 1.0100 1.0100
Volume 1,067,500 1,067,500
Avg Vol 1,891,005 1,891,005
Stochastic %K 74.80% 74.80%
Weighted Alpha -66.12 -66.12
5-Day Change -0.0900 (-8.04%) -0.0900 (-8.04%)
52-Week Range 0.6603 - 2.4300 0.6603 - 2.4300
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 117,056
  • Shares Outstanding, K 115,897
  • Annual Sales, $ 266,960 K
  • Annual Income, $ 28,510 K
  • EBIT $ -112 M
  • EBITDA $ -106 M
  • 60-Month Beta 1.01
  • Price/Sales 0.48
  • Price/Cash Flow 3.81
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 146.69% ( +27.34%)
  • Historical Volatility 107.42%
  • IV Percentile 71%
  • IV Rank 25.04%
  • IV High 567.48% on 06/05/24
  • IV Low 6.15% on 08/15/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 222
  • Volume Avg (30-Day) 325
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 13,623
  • Open Int (30-Day) 14,138

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.37
  • Number of Estimates 2
  • High Estimate -0.24
  • Low Estimate -0.49
  • Prior Year -0.38
  • Growth Rate Est. (year over year) +2.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7235 +42.36%
on 04/09/25
Period Open: 0.9600
1.1600 -11.21%
on 04/23/25
+0.0700 (+7.29%)
since 03/25/25
3-Month
0.7235 +42.36%
on 04/09/25
Period Open: 1.2400
1.3900 -25.90%
on 01/30/25
-0.2100 (-16.94%)
since 01/24/25
52-Week
0.6603 +55.99%
on 11/05/24
Period Open: 1.9300
2.4300 -57.61%
on 12/03/24
-0.9000 (-46.63%)
since 04/25/24

Most Recent Stories

More News
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

CHRS : 1.0300 (+1.98%)
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes

CHRS : 1.0300 (+1.98%)
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

CHRS : 1.0300 (+1.98%)
Coherus BioSciences: Q4 Earnings Snapshot

Coherus BioSciences: Q4 Earnings Snapshot

CHRS : 1.0300 (+1.98%)
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

CHRS : 1.0300 (+1.98%)
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

CHRS : 1.0300 (+1.98%)
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

CHRS : 1.0300 (+1.98%)
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

CHRS : 1.0300 (+1.98%)
Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CHRS : 1.0300 (+1.98%)
Coherus BioSciences Initiates Phase 2 Study of Casdozokitug Combined with Toripalimab and Bevacizumab for Liver Cancer Treatment

Coherus BioSciences initiates a Phase 2 study evaluating casdozokitug, toripalimab, and bevacizumab for liver cancer treatment.Quiver AI SummaryCoherus BioSciences has launched a randomized Phase 2 study...

CHRS : 1.0300 (+1.98%)

Business Summary

Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid...

See More

Key Turning Points

3rd Resistance Point 1.1167
2nd Resistance Point 1.0833
1st Resistance Point 1.0567
Last Price 1.0300
1st Support Level 0.9967
2nd Support Level 0.9633
3rd Support Level 0.9367

See More

52-Week High 2.4300
Fibonacci 61.8% 1.7540
Fibonacci 50% 1.5452
Fibonacci 38.2% 1.3363
Last Price 1.0300
52-Week Low 0.6603

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective